Earnings Releases·Oct 27, 2026, 4:07 PM ET

Pulmonx Corporation — Third Quarter 2026 Earnings Summary

Worldwide revenue grew 6% year-over-year to $22.8 million, while net loss narrowed 40% to $8.4 million and Adjusted EBITDA loss decreased 57% to $3.5 million.
Full-year 2026 revenue guidance remains $90 million to $92 million, with gross margin guidance raised to approximately 77% and operating expenses projected between $108 million and $109 million.
International growth was impacted by a temporary pause in China sales due to distributor registration renewal, though U.S. revenue rose 7% and the global commercial team has been restructured.
The Zephyr Endobronchial Valve maintains its status as a standard of care in over 25 countries, supported by recent FDA Premarket Approval for the device.